



ASX Release

Acrux Investor Webinar

Melbourne, Australia; 25 February 2025

Acrux Limited (ASX:ACR, “Acrux” or the “Company”) will host an Investor Webinar where management will present the results for the Company for the half year ended 31 December 2024. Questions that are sent in advance of the webinar to info@acrux.com.au or michael.kotsanis@acrux.com.au will be addressed immediately after the presentation.

Investor Webinar details:

Date: Thursday 27 February 2025

Time: 10.00am Melbourne, Sydney, Canberra, Hobart
9.30am Adelaide
9.00am Brisbane
7.00am Perth
12.00pm New Zealand

Topic: Acrux Investor Webinar

Please click on this link to join the webinar:

<https://us02web.zoom.us/j/82063026236>

Webinar ID: 820 6302 6236

Phone one-tap:

+61871501149,,82063026236# Australia
+61280156011,,82063026236# Australia

Join via audio:

+61 8 7150 1149 Australia
+61 2 8015 6011 Australia
+61 3 7018 2005 Australia
+61 7 3185 3730 Australia
+61 8 6119 3900 Australia
+64 4 886 0026 New Zealand
+64 9 884 6780 New Zealand
+64 3 659 0603 New Zealand



Approved for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis
Acrux Limited
CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

For further information on Acrux, visit www.acrux.com.au